Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vir Biotechnology (VIR – Research Report) and Atara Biotherapeutics (ATRA – Research Report).
Vir Biotechnology (VIR)
Goldman Sachs analyst Paul Choi maintained a Buy rating on Vir Biotechnology on November 2 and set a price target of $28.00. The company’s shares closed last Friday at $8.76, close to its 52-week low of $7.72.
According to TipRanks.com, Choi is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vir Biotechnology with a $31.14 average price target, which is a 273.8% upside from current levels. In a report issued on November 2, Leerink Partners also maintained a Buy rating on the stock with a $24.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Atara Biotherapeutics (ATRA)
Goldman Sachs analyst Salveen Richter maintained a Sell rating on Atara Biotherapeutics on November 1 and set a price target of $3.00. The company’s shares closed last Friday at $1.29, close to its 52-week low of $1.17.
According to TipRanks.com, Richter is a 5-star analyst with an average return of
Atara Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $14.53.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VIR:
- Vir Biotechnology files automatic mixed securities shelf
- Vir Biotechnology reports Q3 EPS ($1.22), consensus ($1.21)
- Vir Biotechnology appoints Jennifer Towne, Ph.D., as Chief Scientific Officer
- Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
- Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
